Showing posts with label Pharmaceuticals. Show all posts
Showing posts with label Pharmaceuticals. Show all posts
November 01, 2013
October 01, 2013
September 05, 2013
September 03, 2013
03/09/2013: International InsectCentre; intercrop planting; South African grain differential
A range of companies, government agencies and universities have set up an international organisation with the aim of promoting insects as a viable feed and pharmaceutical resource.
The International
InsectCentre (IIC), based in Brabant, the Netherlands will develop joint
projects and rally towards breakthroughs in international legislation
and regulation. As a cooperative, the Centre will also help parties who wish to contribute to the promotion of insects for food.
According to research by Ohio State University's College of food, Agricultural and Environmental Sciences, planting soybeans into standing wheat not only results in higher
yields but also offers growers' a financial boost.
Steve Prochaska, an Ohio
State University Extension field specialist and member of the
university’s Agronomic Crops Team added that the technique, known as modified relay intercropping, results in the ability to capture 66 percent of the traditional growing
season, which allows production of a second crop through late May or early June.
South African news broadcaster eNCA recently reported on the proposed increase in location differentials by the Johannesburg Stock Exchange (JSE).
The location differentials focus on the cost of transporting grain from registered silos in
different parts of the country to a central selling point in The West Rand District of South Africa.
Grain association, GrainSA commented on the proposal, stating that many grain farmers deliver much of their product to local
buyers and the location differential causes them to pay thousands in “imaginary” transport costs.
Watch the full news report here.
| Wheat at the anthesis stage. Face view (left) and side view (right) & Wheat ear at the late milk (Photo credit: Wikipedia) |
March 17, 2011
Pfizer Animal Health begins integration with Alpharma
With the acquisition of King Pharmaceuticals by Pfizer, Inc, announced on February 28, Pfizer Animal Health will begin integrating Alpharma, LLC into its existing business.
The integration of Alpharma allows Pfizer Animal Health to build on its already broad product portfolio of biologics, medicines and immuno-diagnostics. “Pfizer Animal Health welcomes Alpharma colleagues and the company’s respected products and services,” said Clint Lewis, President of U.S. Operations for Pfizer Animal Health.
“Today marks another important milestone in Pfizer Animal Health’s evolution in offering veterinarians, nutritionists and all our customers a more comprehensive portfolio of unique products and services. It also further demonstrates our commitment to becoming a complete solutions provider for our customers.”
This blog is written by Martin Little The Global Miller, published and supported by the GFMT Magazine from Perendale Publishers.
The integration of Alpharma allows Pfizer Animal Health to build on its already broad product portfolio of biologics, medicines and immuno-diagnostics. “Pfizer Animal Health welcomes Alpharma colleagues and the company’s respected products and services,” said Clint Lewis, President of U.S. Operations for Pfizer Animal Health.
“Today marks another important milestone in Pfizer Animal Health’s evolution in offering veterinarians, nutritionists and all our customers a more comprehensive portfolio of unique products and services. It also further demonstrates our commitment to becoming a complete solutions provider for our customers.”
This blog is written by Martin Little The Global Miller, published and supported by the GFMT Magazine from Perendale Publishers.
March 16, 2011
Animal Health Int & Lextron to merge
Lextron, Inc, a Colorado-based distributor of livestock vaccines and supplements, announced its plans to buy competitor Animal Health International, Inc, for about US$251 million.
In a joint statement released this week the companies stated that privately-held Lextron will pay US$4.25 a share for all outstanding Animal Health stock or approximately US$111 million plus assume US$140 million of Animal Health’s debt.
According to John Adent, President and CEO for Lextron, “This merger provides an opportunity for us to collectively create the country’s premier animal health business.” Read more ...
This blog is written by Martin Little The Global Miller, published and supported by the GFMT Magazine from Perendale Publishers.
In a joint statement released this week the companies stated that privately-held Lextron will pay US$4.25 a share for all outstanding Animal Health stock or approximately US$111 million plus assume US$140 million of Animal Health’s debt.
According to John Adent, President and CEO for Lextron, “This merger provides an opportunity for us to collectively create the country’s premier animal health business.” Read more ...
This blog is written by Martin Little The Global Miller, published and supported by the GFMT Magazine from Perendale Publishers.
Subscribe to:
Posts (Atom)


